Name | Nelfinavir |
Synonyms | AG 1341 AG1341 AG-1341 nefinavir NELFINAVIR Nelfinavir 8a-beta))-a-bet Nelfinavir Regeoisomer 3-isoquinolinecarboxamide,n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hy (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide (3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide N-tert-butyl-2-[2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide |
CAS | 159989-64-7 |
EINECS | 1533716-785-6 |
InChI | InChI=1/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1 |
Molecular Formula | C32H45N3O4S |
Molar Mass | 567.78 |
Density | 1.22±0.1 g/cm3(Predicted) |
Melting Point | 185-186 °C |
Boling Point | 786.8±60.0 °C(Predicted) |
Specific Rotation(α) | D -119.23° (c = 0.26 in methanol) |
Flash Point | 429.7°C |
Water Solubility | 7g/L(temperature not stated) |
Vapor Presure | 4.38E-26mmHg at 25°C |
pKa | pKa1 6.0; pKa2 11.06(at 25℃) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Refractive Index | 1.618 |
Use | Nelfinavir (AG-1341) is an effective oral bioavailable HIV-1 protease inhibitor (Ki = 2 nM) for HIV infection. Nelfinavir (AG-1341) is a broad-spectrum anticancer agent. |
In vitro study | Nelfinavir (AG1341) (1-10 μM; 48 hours) inhibits the proliferation of multiple myeloma cells. Nelfinavir inhibits 26S chymotrypsin-like proteasome activity, impairs proliferation and triggers apoptosis of the myeloma cell lines and fresh plasma cells. Nelfinavir (1-10 μM; 17 hours) induces apoptosis of multiple myeloma cell lines. Nelfinavir (5 μM; 0-24 hours) decreases the phosphorylation of AKT. Nelfinavir activates the cleavage of caspase-3, decreases the phosphorylation of AKT, STAT-3, ERK1/2, and activates the pro-apoptotic pathway of the unfolded protein response system. Cell Proliferation Assay Cell Line: RPMI, LP1, U266, OPM2 and MM1S cells Concentration: 1, 2, 5, 10 μM Incubation Time: 48 hours Result: Inhibited the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines in a dose-dependent manner with an IC 50 of 1-5 μM. Apoptosis Analysis Cell Line: LP1 and U266 cells Concentration: 1-10 μM Incubation Time: 17 hours Result: Induced a dose-dependent increase in the percentage of annexin V + /propidium iodide + cells. Western Blot Analysis Cell Line: U266 cells Concentration: 5 μM Incubation Time: 0-24 hours Result: The level of AKT phosphorylation in U266 cells decreased. |
In vivo study | Nelfinavir (AG1341) (75 mg/kg; i.p.; 5 days a week for 21 days) decreases multiple myeloma cell growth in NOD/SCID mice. Animal Model: NOD/SCID mice (bearing U266-luc cells) Dosage: 75 mg/kg Administration: I.p.; 5 days a week for 21 days Result: Decreased MM cell growth in NOD/SCID mice. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.761 ml | 8.806 ml | 17.612 ml |
5 mM | 0.352 ml | 1.761 ml | 3.522 ml |
10 mM | 0.176 ml | 0.881 ml | 1.761 ml |
5 mM | 0.035 ml | 0.176 ml | 0.352 ml |